Why the study?
The prognostic value of G protein-coupled receptor autoantibodies for MACEs in patients with STEMI remains unclear.
Do elevated serum levels of G protein-coupled receptor autoantibodies at admission predict major adverse cardiovascular events in STEMI patients undergoing primary PCI?
Cohort (n=436)
Do elevated serum levels of G protein-coupled receptor autoantibodies at admission predict major adverse cardiovascular events in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated β1- and M2-autoantibody levels at admission are independent predictors of one-year MACEs in STEMI patients undergoing primary PCI, and their combined assessment may enhance early risk stratification.
BACKGROUND G protein-coupled receptor autoantibodies (GPCR-AAs) have been implicated in various cardiovascular disorders. However, their prognostic value for major adverse cardiovascular events (MACEs) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. METHODS In this prospective cohort study, 436 STEMI patients undergoing primary percutaneous coronary intervention (PPCI) completed a one-year follow-up. Serum levels of five GPCR-AAs (β1-, β2-, α1-, AT1-, and M2-AAs) were measured at admission using ELISA. Patients were grouped based on the occurrence of MACEs, and associations of GPCR- AAs with MACEs were evaluated using multivariate Cox regression. RESULTS Compared with the non-MACE group, the optical density(OD) values and positivity rates of the β1-AA levels (69.6% vs 19.6%) and M2-AA levels (82.6% vs 60.2%) in patients with STEMI were significantly higher in the MACE group. Multivariate Cox regression analysis revealed that β1-AA [HR(95%CI)1.11(1.06-1.16),p < 0.001] and M2-AA [HR(95%CI)1.14(1.05-1.23),p = 0.001] were regarded as predictors for the incidence of MACEs in patients with STEMI after PPCI. The combination of β1-AA and M2-AA has the highest predictive power to predict MACEs. The area under the curve (AUC) of the integrated 2-marker panel was 0.807 (95% CI, 0.75-0.86, p < 0.001). CONCLUSIONS Elevated β1- and M2-Autoantibody levels at admission are independent predictors of one-year MACEs in STEMI patients undergoing PPCI. Their combined assessment enhances early risk stratification for guiding post-infarction management.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=436). Serum levels of GPCR-AAs (β1-AA and M2-AA) was evaluated on Major adverse cardiovascular events (MACEs) (HR 1.11, 95% CI 1.06-1.16, p=< 0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: